“Expanding our U.S. distribution network remains a key priority for the Company,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “These agreements enhance our access to selected U.S. markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results